WALTHAM, Mass.–Thermo Fisher Scientific has introduced Gibco VaxEvo CD 293 Medium, a new cell culture product designed to improve adenovirus vaccine production and support the development and manufacturing of viral vectors.
The chemically defined, animal origin-free medium is designed to support the growth of suspension HEK293 cells while enabling high adenovirus productivity. The product is available in liquid and Advanced Granulation Technology (AGT) formats, allowing vaccine developers to use it throughout process development, scale-up and manufacturing.
The launch addresses growing demand for cell culture technologies that can support efficient adenovirus production while reducing the complexity of manufacturing processes.
According to Thermo Fisher Scientific, VaxEvo CD 293 Medium is intended for vaccine developers and manufacturers working in human and animal health, particularly those using suspension HEK293 cells for adenovirus-based applications.
“Manufacturing readiness begins well before a process reaches the plant. The choices vaccine developers make during process development can shape how they evaluate performance, complexity and the path to scale,” said Alex Cherkassky, Vice President and General Manager of Thermo Fisher Scientific’s Cell Culture Business.
“We developed Gibco VaxEvo CD 293 Medium as a purpose-built starting point to help customers advance suspension-based adenovirus HEK293 processes with greater confidence.”
In laboratory benchmarking studies involving HEK293 cells, the new medium demonstrated adenovirus type 5 (Ad5) production levels comparable to those achieved with selected competing products. In some comparisons, adenovirus titers were as much as 5.7 times higher.
The company also reported that VaxEvo CD 293 Medium achieved comparable or higher adenovirus titers without requiring a dedicated nutrient feed, while certain benchmark products were tested with their recommended feeds.
The findings suggest that the medium could help simplify upstream manufacturing workflows by reducing the need for additional feeding steps while maintaining cell growth and virus production.
Beyond adenovirus vaccines, the medium is designed for applications involving adenoviral vectors and oncolytic viruses, which are used in various vaccine development and therapeutic research programs.
Thermo Fisher Scientific said the product’s chemically defined formulation and absence of animal-derived components are intended to support consistent cell culture conditions during development and manufacturing.
The medium will be offered in liquid formulations and multiple AGT package sizes to accommodate different production requirements.
The introduction expands Thermo Fisher Scientific’s Gibco cell culture portfolio, which provides technologies and materials used in biopharmaceutical research, vaccine development and manufacturing.


